DOB:

Patient Report

Patient ID:
Age:
Ordering Physician:
Specimen ID:
Sex:

labcorp

Ordered Items: **NMR LipoProfile+Lipids+Graph; Hgb A1c with eAG Estimation; Lipoprotein (a); C-Reactive Protein, Cardiac; Homocyst(e)ine**

Date Collected:	Date Received:	Date Reported:	Fasting:

NMR LipoProfile+Lipids+Graph

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
LDL Particle Number[01]				
LDL-P[A, 01]	859	11/19/2021	nmol/L	<1000
		Low	< 1000	
		Moderate	1000 - 1299	
		Borderline-High	1300 - 1599	
		High	1600 - 2000	
		Very High	> 2000	
Lipids[01]				
LDL-C (NIH Calc)[01]	62	11/19/2021	mg/dL	0-99
		Optimal	< 100	
		Above optimal	100 - 129	
		Borderline	130 - 159	
		High	160 - 189	
		Very high	> 189	
HDL-C[A, 01]	78	11/19/2021	mg/dL	>39
Triglycerides[A, 01]	101	11/19/2021	mg/dL	0-149
Cholesterol, Total[A, 01]	158	11/19/2021	mg/dL	100-199
LDL and HDL Particles[01]				
HDL-P (Total)[A, 01]	32.5	11/19/2021	umol/L	>=30.5
Small LDL-P[A, 01]	<90	11/19/2021	nmol/L	<=527
LDL Size[A, 01]	21.5	11/19/2021	nm	>20.5

```
** INTERPRETATIVE INFORMATION**
PARTICLE CONCENTRATION AND SIZE
                  <--Lower CVD Risk   Higher CVD Risk-->
LDL AND HDL PARTICLES   Percentile in Reference Population
HDL-P (total)        High     75th    50th    25th    Low
                     >34.9    34.9    30.5    26.7    <26.7
Small LDL-P          Low      25th    50th    75th    High
                     <117     117     527     839     >839
LDL Size   <-Large (Pattern A)->    <-Small (Pattern B)->
                  23.0    20.6           20.5      19.0
```

Comment:[01]

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance Score[01]				
LP-IR Score[A, 01]	<25			<=45

INSULIN RESISTANCE MARKER

labcorp

Date Created and Stored

Final Report

NMR LipoProfile+Lipids+Graph (Cont.)

	<--Insulin Sensitive		Percentile in Reference Population		Insulin Resistant-->
Insulin Resistance Score					
LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63

Comment: [01]

LP-IR Score is inaccurate if patient is non-fasting.
The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

PDF [01]	.	.	11/19/2021

Hgb A1c with eAG Estimation

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Hemoglobin A1c [02]	4.9	11/19/2021	%	4.8-5.6

Please Note: [02]

Prediabetes: 5.7 - 6.4
Diabetes: >6.4
Glycemic control for adults with diabetes: <7.0

Estim. Avg Glu (eAG)	94	94	11/19/2021	mg/dL

Lipoprotein (a)

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Lipoprotein (a) [01]	29.9		nmol/L	<75.0

Note: Values greater than or equal to 75.0 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities.

C-Reactive Protein, Cardiac

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
C-Reactive Protein, Cardiac [02]	0.32		mg/L	0.00-3.00

Relative Risk for Future Cardiovascular Event	
Low	<1.00
Average	1.00 - 3.00
High	>3.00

Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Homocyst(e)ine [02]	12.4		umol/L	0.0-17.2

LabCorp
Laboratory Corporation of America

Medical Director:

Specimen Number	Patient ID	Account Number	Account Phone	Account Fax

Patient Last Name	Patient First Name	Account Address
		Request A Test, LTD. 7027 Mill Road Suite 201 BRECKSVILLE, OH 44141

Age	Date of Birth	Sex	Fasting
			YES

Control Number	NPI

Date Collected	Date Entered	Date and Time Reported	Physician ID & Name	Page Number
				1 of 2

❖ NMR LipoProfile ® test

		Reference Interval[1]				
		Percentile[1]	20th	50th	80th	95th
	nmol/L	Low	Moderate	Borderline High	High	Very High
LDL-P (LDL Particle Number)	**859**	**< 1000**	**1000 - 1299**	**1300 - 1599**	**1600 - 2000**	**> 2000**

1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

❖ Lipids

	mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
LDL-C (calculated)	**62**	**< 100**	**100 - 129**	**130 - 159**	**160 - 189**	**≥ 190**

	mg/dL		mg/dL		mg/dL
HDL-C	**78**	**Triglycerides**	**101**	**Total Cholesterol**	**158**
	Desirable ≥ 40		Desirable < 150		Desirable < 200

Historical Reporting

LDL-P



LDL-C



❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

Issued or Pending PATENTS	The NMR LipoProfile ® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030	CLIA Number

LabCorp
Laboratory Corporation of America

Medical Director:

Specimen Number	Patient ID	Account Number	Account Phone	Account Fax

Patient Last Name	Patient First Name	Account Address
		Request A Test, LTD. 7027 Mill Road Suite 201 BRECKSVILLE, OH 44141

Age	Date of Birth	Sex	Fasting
			YES

Control Number	NPI

Date Collected	Date Entered	Date and Time Reported	Physician ID & Name	Page Number
				2 of 2

PARTICLE CONCENTRATION AND SIZE

❖ LDL and HDL Particles

Lower CVD Risk ← → Higher CVD Risk

Percentile in Reference Population①

		μmol/L	high	75th	50th	25th	low
HDL-P (total)		32.5		34.9	30.5	26.7	

		nmol/L	low	25th	50th	75th	high
SMALL LDL-P		<90		117	527	839	

		nm	23.0	Large (Pattern A)	20.6	20.5	Small (Pattern B)	19.0
LDL SIZE		21.5						

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance Score②③

Insulin Sensitive ← → Insulin Resistant

Percentile in Reference Population①

		0-100	insulin sensitive	25th	50th	75th	insulin resistant
LP-IR SCORE**		<25		27	45	63	

** The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score has not been cleared by the US Food and Drug Administration.

Clinician Notes

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.